

22nd February, 2015



Dear Editor,

Please find enclosed the edited manuscript in Word format (16099-revised).

Title: Management of hepatitis delta: need for novel therapeutic options

Author: Zaigham Abbas, Minaam Abbas

Name of Journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 16099

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer. Changes are in the red font

Review 1 (03020543)

The paper could benefit from one or more figures that illustrate the starting points of the respective options.

As this is an editorial, not a review article, including figures may not be essential.

Reviewer 2 (00068251)

The abbreviation of the "CDH" should be defined in the text at its first occurrence and CDH should be used thereafter.

I have not used CDH anywhere in the text

2. The content of the paragraph which begins as "Myrcludex B was added to" can be more clearly expressed by using an algorithm, which will be more comprehensible for readers.

I have modified the paragraph to make it clearer and included my comments at the end

3. I have thoroughly checked the paper twice. In terms of grammar, it is OK, however, four sentences (see below) need touch-up work –

I have modified these sentences

Reviewer 3

This review looks at new reports of receptor for HBV and HDV. It also deals heavily with unreviewed data published so far only as several abstracts from work of others presented at an inte

national meeting. The other criticism is that the author does not offer much evaluation of the studies cited.

This editorial deals with the new research so some of the work cited is in the abstract form. I have added evaluation of these studies where needed.

The statement that L protein mediates interaction with proteoglycans may be incorrect. Are not domains of S also used, including the extracellular antigenic loop?

Please see my reference 20

Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 2014; 147: 48-64

2. It has already been shown that HDV large antigen adopts one form of isoprenylation, farnesylation.

Agreed. Please see the section Prenylation inhibitors second paragraph

3. A reduction of HDV in patients with lonafernib is interesting. However the effect was less than 10 fold and patients would have to be treated for much longer than 3 weeks and with possible side effects.

Comments added in the text

4. The acceptance of the value of an antisense study seems unreasonable. It is not available for reviewers. It was probably done in cultured cells. How effective was it? Does the author think it something that could be done in patients.

I think so. Please see my reference

31. Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006; 33: 533-540 [

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

Dr. Zaigham Abbas, FCPS, FRCP, Department of Hepatogastroenterology, Sindh Institute of Urology and Transplantation, Chand Bibi Road, Karachi 75500, Pakistan. drzabbas@gmail.com

Telephone: +92-21-32728998

Fax: +92-21-32728998